Endo Osteoporosis Follow Up - Adult

Subjective:
Chief Complaint:
Follow-up diabetes management

History of Present Illness:
Mr. Johnson is a male patient presenting for follow-up of diabetes management. He reports feeling generally well since the last visit, with occasional mild fatigue. He denies new symptoms such as dizziness, vision changes, or increased urinary frequency. He does report intermittent numbness in his toes. There have been no episodes of hypoglycemia, including no symptoms of shakiness, diaphoresis, or lightheadedness. Mr. Johnson monitors his capillary blood glucose at home approximately three times per week, with typical morning values between 7 and 8 millimoles per liter. He remains adherent to his prescribed medications, metformin and gliclazide, without adverse effects. Dietary intake has improved with increased consumption of vegetables, and he engages in regular ambulation, walking most days unless weather prohibits. He denies any recent falls or significant unsteadiness, though he notes mild slowness when rising from a seated position. There are no additional concerns reported at this time.

Past Medical History:
Type 2 diabetes mellitus without complications (E11.9). No other significant past medical history provided.

Social History:
Mr. Johnson reports increased consumption of vegetables and regular ambulation, walking most days unless weather prohibits. No information provided regarding occupation, smoking status, alcohol use, drug use, or living situation.

The Review of Systems:
Constitutional – no fever, chills, weight loss, weight gain, night sweats, fatigue, or weakness. Cardiovascular – no chest pain, heart palpitations, dizziness. Gastrointestinal – no nausea, vomiting, diarrhea, or constipation. No problems swallowing. No abdominal pain or bloating. Musculoskeletal – no joint tenderness, redness or swelling. No backache or bone pain. No dizziness, no vision changes, no tingling in feet, no increased trips to the bathroom, no episodes of low blood sugar, no feeling shaky, no feeling sweaty, no feeling lightheaded, no recent falls, no feeling unsteady.

Allergies:
No allergies reported.

Current Medications:
Metformin and gliclazide, taken every morning and evening. No problems with medications.

Past Surgical History:
No surgical history provided.

Assessment:
Problem:
Type 2 diabetes mellitus without complications (E11.9), follow-up for ongoing management.

Differential Diagnosis:
1. Type 2 diabetes mellitus with diabetic polyneuropathy (E11.42).
2. Other fatigue (R53.83).

Clinical Impression:
Mr. Johnson is a male patient with type 2 diabetes mellitus who presents for routine follow-up. He reports stable glycemic control, adherence to medications, and lifestyle modifications. He notes intermittent numbness in his toes, suggestive of possible early diabetic peripheral neuropathy. Laboratory results indicate a hemoglobin A1c of 7.2 percent, with stable renal function and lipid profile.

Objective:
Physical Examination:
Constitutional – patient is alert and appears well, in no acute distress. HEENT – head atraumatic and normocephalic, extraocular movements intact, pupils equal, round, and reactive to light and accommodation, no oral lesions. Cardiovascular – regular rate and rhythm, normal heart sounds with no murmurs or added sounds, no jugular venous distension, no peripheral edema, capillary refill time less than two seconds. Respiratory – clear to auscultation bilaterally, no wheezes or crackles. Abdomen – soft, non-tender, no distension or hepatosplenomegaly, normal bowel sounds. Musculoskeletal – no obvious deformities, no tenderness over vertebrae on palpation. Neurologic – strength five out of five in upper and lower extremities, normal gait.

Test Results:
Hemoglobin A1c: 7.2 percent. Renal function and cholesterol levels stable. No additional laboratory or imaging results provided.

Vital Signs:
No vital signs provided.

Plan:
1. Continue current regimen of metformin and gliclazide.
2. Maintain regular home blood glucose monitoring several times per week.
3. Encourage ongoing dietary management with increased vegetable intake.
4. Advise continued regular ambulation as tolerated.
5. Arrange for a foot examination at the next visit due to reported intermittent numbness in toes.
6. Recommend use of supportive footwear at home.
7. Order repeat blood tests in approximately three months to monitor glycemic control and metabolic parameters.
No questions or concerns.

Follow Up:
Follow-up appointment scheduled in approximately three months. Instructed to contact the clinic if any changes or concerns arise before the next visit.

Assessment and Plan:
- Type 2 diabetes mellitus without complications (E11.9): Mr. Johnson reports stable glycemic control with home capillary blood glucose monitoring showing typical morning values between 7 and 8 millimoles per liter. He remains adherent to metformin and gliclazide without adverse effects. Glycated hemoglobin was 7.2 percent on recent laboratory evaluation, which is within the individualized target range. There are no reported episodes of hypoglycemia. Mild intermittent numbness in the toes is noted. 
Plan:
• Continue current regimen of metformin and gliclazide at existing dosages.
• Reinforce home blood glucose monitoring three times per week.
• Maintain dietary modifications with increased vegetable intake.
• Encourage regular ambulation as tolerated.
• Arrange for a comprehensive foot examination at the next visit due to reported intermittent numbness in the toes.
• Advise use of supportive footwear at home.
• Order repeat laboratory studies, including glycated hemoglobin, renal function, and lipid profile, in three months.
• Schedule follow-up appointment in approximately three months to reassess glycemic control and review laboratory results.


- Polyneuropathy, unspecified (G62.9): Mr. Johnson reports intermittent numbness in the toes without associated pain or ulceration. 
Plan:
• Arrange for a detailed foot examination at the next visit to assess for diabetic neuropathy and risk of complications.
• Counsel on daily foot care and the importance of protective footwear.
• Monitor for progression of symptoms or development of new neurological deficits.